沃森生物:2024SustainabilityReport

Message from the Chairman
In 2024, Walvax Biotechnology forged ahead with renewed for multiple consecutive years. To date, we have launched We are driving a green transformation to build a cleaner,
ambition and unwavering commitment. This year, we actively 8 vaccine products with 14 specifications, and an additional low-carbon production system. Walvax Biotechnology
embraced change and focused our efforts on building a mRNA vaccine targeting the Omicron XBB.1.5 variant has integrates green ecological principles and sustainability
dynamic, customer- and market-oriented business framework. been approved for emergency use by Chinese national requirements into every aspect of its operations. We are
These strides marked a new chapter in our pursuit of high- authorities. These achievements reflect the Company's committed to building a company-wide EHS management
quality development. Throughout the year, we remained enduring commitment to public health. In 2024, the Company system that spans all business units, while proactively
committed to strengthening corporate governance, protecting achieved new breakthroughs in several innovative blockbuster addressing the risks and opportunities brought by climate
the environment, and fulfilling our social responsibilities. products and technologies. With continuous improvements in change. We are firmly advancing resource conservation
In doing so, we continuously enhanced our capabilities in quality management, Walvax Biotechnology is honored to be and environmental protection action plans. Through robust
governance, innovation, resilience, competitiveness, and value recognized among the Top 500 Private Enterprises in R&D environmental management systems and the implementation
creation. These efforts not only advanced the Company's Investment 2024 and the Top 10 Most Innovative Non-public of high-standard environmental practices, we strive to
sustainable growth, but also contributed to the broader goal of Enterprises in Yunnan Province 2024. In December 2024, the establish a production system that is clean, low-carbon,
sustainable economic and social development. Yunnan Vaccine Laboratory passed the acceptance inspection and climate-resilient. In 2024, the Company incorporated
and was officially inaugurated. It will serve as a key strategic energy management indicators and targets into its annual
Steady progress paves the way for long-term success, platform for Walvax Biotechnology to advance vaccine R&D performance evaluations. With continued upgrades in
as transformation fuels the Company's enduring growth. and industrialization, facilitate technology commercialization, equipment and technology, and more efficient production-sales
To better implement its development strategy for the new era power industrial growth, and nurture talent. The laboratory coordination, we achieved sustained reductions in energy
and respond more swiftly and effectively to customer needs, will contribute to China's vaccine industry development and consumption, water usage, greenhouse gas emissions, and
Walvax Biotec